儿童、青少年及年轻成人非DIPG 4级胶质瘤的预后因素:一项当代 pooled 机构经验
这项回顾性 pooled 研究纳入97例小于30岁的4级胶质瘤患者,中位年龄23.9岁,91%为胶质母细胞瘤,9%为H3 K27M改变的弥漫性中线胶质瘤。中位无进展生存期20.9个月,中位总生存期79.4个月。多因素分析显示全切除与更好无进展生存期相关,年龄≥15岁与更好总生存期相关,女性和弥漫性中线胶质瘤组织学与更差总生存期相关。
要点
- 女性(HR 2.12)和弥漫性中线胶质瘤组织学(HR 2.79)与更差总生存期相关。
核心结论
- 年龄是WHO 4级胶质瘤的重要预后因素,可能反映肿瘤中与年龄相关的分子改变。
- 弥漫性中线胶质瘤的总生存期比胶质母细胞瘤更差。
- 疾病进展后再次手术和全身治疗显著提高生存率。
- 作者认为需要在该人群中进行前瞻性研究。
研究设计与样本
- 回顾性 pooled 研究,纳入小于30岁、接受现代手术和放疗的4级胶质瘤患者,共97例。
- 中位诊断年龄23.9岁;77例(79%)年龄≥15岁,20例(21%)年龄<15岁。
- 91%为活检证实的胶质母细胞瘤,9%为H3 K27M改变的弥漫性中线胶质瘤。
- 所有患者均接受手术和放疗。
- 采用Kaplan-Meier法和Cox回归分析总生存期和无进展生存期。
主要发现
- 中位无进展生存期20.9个月,中位总生存期79.4个月。
- 仅7%的患者发生2级毒性;62%的患者出现肿瘤进展(28%局部,34%远处)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: WHO grade 4 gliomas are rare in the pediatric and adolescent and young adult (AYA) population. We evaluated prognostic factors and outcomes in the pediatric versus AYA population. METHODS: This retrospective pooled study included patients less than 30 years old (yo) with grade 4 gliomas treated with modern surgery and radiotherapy. Overall survival (OS) and progression-free survival (PFS) were characterized using Kaplan-Meier and Cox regression analysis. RESULTS: Ninety-seven patients met criteria with median age 23.9 yo at diagnosis. Seventy-seven patients were ≥ 15 yo (79%) and 20 patients were < 15 yo (21%). Most had biopsy-proven glioblastoma (91%); the remainder had H3 K27M-altered diffuse midline glioma (DMG; 9%). All patients received surgery and radiotherapy. Median PFS and OS were 20.9 months and 79.4 months, respectively. Gross total resection (GTR) was associated with better PFS in multivariate analysis [HR 2.00 (1.01-3.62), p = 0.023]. Age ≥ 15 yo was associated with improved OS [HR 0.36 (0.16-0.81), p = 0.014] while female gender [HR 2.12 (1.08-4.16), p = 0.03] and DMG histology [HR 2.79 (1.11-7.02), p = 0.029] were associated with worse OS. Only 7% of patients experienced grade 2 toxicity. 62% of patients experienced tumor progression (28% local, 34% distant). Analysis of salvage treatment found that second surgery and systemic therapy significantly improved survival. CONCLUSION: Age is a significant prognostic factor in WHO grade 4 glioma, which may reflect age-related molecular alterations in the tumor. DMG was associated with worse OS than glioblastoma. Reoperation and systemic therapy significantly increased survival after disease progression. Prospective studies in this population are warranted.
引用
- Matsui JK, Allen PK, Perlow HK, et al. Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience. J Neurooncol. 2023. PMID: 37440097. doi:10.1007/s11060-023-04386-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。